The Oral Peptide Race: How 2026's Approvals and Investment Wave Are Reshaping Peptide Drug Development

Key takeaways

• The FDA approved two oral peptide or peptide-mimetic agents in Q1 2026: Eli Lilly's orforglipron (Foundayo) for obesity and Johnson & Johnson/Protagonist's icotrokinra (ICOTYDE) for plaque psoriasis.
• Orforglipron is a small molecule that activates the GLP-1 receptor without injection or food restrictions, while icotrokinra is the first targeted oral peptide to block the IL-23 receptor.
• More than $250 million in new venture capital has been committed in 2026 to oral peptide platforms alone, including Syneron Bio's $150 million Series B and Pinnacle Medicines' $89 million Series B.
• The competitive landscape now includes Novo Nordisk's oral semaglutide, Structure Therapeutics' aleniglipron, and a broad pipeline of macrocyclic and AI-designed oral peptides.
• For UK research-procurement teams, these developments signal growing demand for oral-stable peptide reference standards, new permeability assay reagents, and bioavailability characterisation tools.

A sector milestone, twice over

The first quarter of 2026 produced two regulatory decisions that, taken together, mark a structural shift in how the pharmaceutical industry thinks about peptide medicine delivery.

On 1 April 2026, the FDA approved Foundayo (orforglipron), Eli Lilly's once-daily oral pill for adults with obesity or overweight with weight-related medical problems. The approval was notable on two counts. First, orforglipron is a small-molecule GLP-1 receptor agonist — technically not a peptide itself — that mimics the action of the GLP-1 hormone without requiring an injection, an absorption enhancer, or food or water restrictions at dosing. Second, the FDA approved the compound 294 days ahead of its scheduled PDUFA date, marking the fastest approval of a new molecular entity since 2002, under the Commissioner's National Priority Voucher programme.

Just two weeks earlier, in March 2026, the FDA approved icotrokinra, marketed as ICOTYDE, for the treatment of moderate-to-severe plaque psoriasis in adults and paediatric patients aged 12 and over. Developed by Johnson & Johnson in partnership with Protagonist Therapeutics, ICOTYDE is the first and only targeted oral peptide that precisely blocks the Interleukin-23 receptor. It is also in Phase 3 development for psoriatic arthritis and ulcerative colitis, per Protagonist's pipeline disclosures.

Together, the two approvals confirm what many in the field had predicted but few had seen delivered at scale: that oral peptide and peptide-mimetic formulations can produce clinically meaningful outcomes with acceptable tolerability.

The clinical evidence behind the approvals

The case for orforglipron rests on Phase 3 data showing approximately 14.7% body weight loss at 72 weeks in adults with obesity without diabetes. Orforglipron achieved 7.5% to 11.2% weight loss across doses in pivotal trials and carries a distinct metabolic profile, requiring dose adjustments when co-administered with cytochrome P450 3A4 inhibitors or inducers. In a separate head-to-head Phase 3 trial published in The Lancet, orforglipron delivered superior blood sugar control and weight loss compared to oral semaglutide in type 2 diabetes, according to Eli Lilly's own disclosures.

The icotrokinra data package is similarly robust. Phase 3 ICONIC-ADVANCE 1 and 2 and ICONIC-LEAD studies supported ICOTYDE as a differentiated oral therapy for moderate-to-severe psoriasis, demonstrating durable efficacy and a favourable safety profile in a once-daily pill.

The investment wave

Regulatory validation has been matched by a surge in capital directed at oral peptide platforms.

Syneron Bio, a Beijing-based peptide drug discovery company, closed a $150 million Series B round to support its macrocyclic peptide development platform, just four months after closing its Series A and A+ rounds totalling nearly $100 million. Syneron leverages artificial intelligence through its proprietary Synova platform; macrocyclic peptides have been described as a "goldilocks" drug class due to their ability to bridge the gap between small molecules and biologics, enabling the targeting of traditionally difficult disease pathways. The round attracted backing from AstraZeneca — consistent with the $3.4 billion-potential platform deal Syneron announced with AstraZeneca in March 2025.

In parallel, Pinnacle Medicines, an oral peptide specialist with operations in Shanghai and Pennsylvania, closed an oversubscribed $89 million Series B round co-led by LAV and Foresite Capital, with participation from RA Capital Management, OrbiMed, Quan Capital, Hankang Capital, and Logos Capital. Proceeds will support the advancement of Pinnacle's lead programmes through clinical proof of concept, with an initial focus on immunology and cardiometabolic diseases. The company's platform integrates physics-based molecular simulations, AI-enabled design, and advanced peptide chemistry to rationally design and optimise peptide medicines.

The broader M&A context reinforces the direction of travel. According to PwC's 2026 midyear life sciences outlook, deal activity in the first quarter of 2026 focused on differentiated science, GLP-1 expansion, and next-generation modalities, with PLS deal value surpassing $65 billion — the strongest quarter since 2020.

A broadening competitive landscape

The appetite for oral peptide delivery extends well beyond the two approved agents.

Novo Nordisk launched an oral form of its blockbuster Wegovy (semaglutide) at the beginning of 2026 and has already seen strong uptake, and recently inked a $2.1 billion pact with Vivtex to formulate new oral delivery methods. Merck licensed Cyprumed's oral peptide delivery platform for $493 million, signalling that platform-level oral delivery technology is itself a significant commercial asset.

Further along the pipeline, Structure Therapeutics reported 44-week topline data from the ACCESS II Phase 2 study of its oral GLP-1 receptor agonist aleniglipron in March 2026, showing placebo-adjusted weight loss of up to 16.3%, which the company described as the highest efficacy demonstrated among oral GLP-1 receptor agonists at that data cut. Structure's results have drawn significant industry attention given the magnitude of the response relative to approved agents.

Pfizer is advancing danuglipron, a small-molecule GLP-1 agonist, in a Phase 3 programme following formulation revisions. Eli Lilly itself has entered IND-enabling studies for PN-477, a triple GLP-1/GIP/glucagon agonist peptide, with Phase 1 initiation of an oral formulation anticipated in 2027, per Protagonist's pipeline. Amycretin, a combined GLP-1 and amylin receptor agonist from Novo Nordisk, is also in development as an oral formulation, with Phase 1 data showing early promise.

The technical challenge that remains

The surge in approvals and capital should not obscure the fact that oral peptide delivery remains technically demanding. Most peptides are susceptible to proteolytic degradation in the gastrointestinal tract, have low intrinsic membrane permeability due to molecular weight and polarity, and require formulation strategies — cyclisation, N-methylation, lipidation, or co-formulation with absorption enhancers such as SNAC — to achieve systemic exposure.

Orforglipron succeeds precisely because it is not a peptide in the conventional sense: as a non-peptide small molecule, it is cheaper and simpler to manufacture than peptide-based oral GLP-1 agents, and its oral bioavailability is inherent rather than formulation-dependent. Icotrokinra, by contrast, is a true cyclic peptide that has overcome the permeability barrier through Protagonist's proprietary cyclisation chemistry — a harder technical achievement and one that explains why its approval drew particular attention from the research community.

Implications for UK research-procurement teams

The oral peptide wave has several practical consequences for laboratories procuring peptide tools and reference materials.

Reference standards and analogues. As approved oral agents enter post-approval research programmes, demand for high-purity reference standards of icotrokinra, orforglipron, and pipeline oral candidates is likely to increase. Procurement teams should verify that Certificate of Analysis documentation from suppliers includes mass spectrometry confirmation and HPLC purity data at the ≥98% threshold typically required for pharmacokinetic and metabolic stability studies.

Permeability and metabolic stability assays. The oral peptide design question — whether a candidate can survive the gastrointestinal environment and reach systemic circulation — requires Caco-2 permeability assays, P-gp efflux measurements, and CYP3A4 metabolic stability panels as standard. Procurement of reagents and cell lines for these assays is likely to rise as more laboratories establish oral peptide characterisation workflows.

Manufacturing and supply chain scrutiny. Several of the well-funded oral peptide platforms — Syneron Bio, Pinnacle Medicines — have significant R&D operations in China. Procurement professionals should monitor developments around the BIOSECURE Act and any UK government guidance on supply-chain provenance for research reagents, particularly where primary manufacture sits outside the UK or EU.

Regulatory context. Icotrokinra is also under review for EU and Canadian approval, according to the Drugs first-approval summary. UK procurement teams tracking MHRA equivalence pathways for research-grade supply should monitor whether the EU approval, once granted, creates a recognised reference point for MHRA oversight of related research compounds.

The oral peptide pipeline is not a distant prospect: it is commercially active, clinically validated, and attracting sustained institutional capital. For research-procurement professionals, the practical implication is that the toolkit required to characterise peptide candidates — and the regulatory benchmarks against which research-grade material is assessed — is becoming more demanding, not less.

This briefing draws on publicly available regulatory filings, peer-reviewed publications, and press releases. It does not constitute legal, regulatory, or investment advice. Regulatory status of individual compounds should be confirmed against current official sources prior to procurement decisions.